Zydus Cadila Readies Injectables Push Amid Tepid US Growth Outlook
COVID-19 Vaccine Found Safe In Phase I Trials
Zydus Cadila expects domestic sales to improve and the US generics business to grow in “mid to high” single digits during FY21 after both saw a coronavirus-related hit in Q1. Meanwhile, approvals for a few biologics are expected, its COVID-19 vaccine candidate has just entered Phase II studies and remdesivir launch looms.
